<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306694</url>
  </required_header>
  <id_info>
    <org_study_id>e11104</org_study_id>
    <nct_id>NCT02306694</nct_id>
  </id_info>
  <brief_title>Prospective Biomarkers of Bone Metabolism in Hemophilia A</brief_title>
  <official_title>Prospective Biomarkers of Bone Metabolism in Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the major shortcomings in studying bone disease in hemophilia is the lack of fracture
      outcome data demonstrating the clinical significance of decreased BMD and altered bone
      biomarkers in the hemophilia population. This study demonstrates that PwH have an increased
      risk of fracture compared to the general population and that the issue of bone health will
      increase in importance as the PwH population ages.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study to determine the impact of factor replacement on bone biomarkers in up
      to 20 hemophilia A subjects. Subjects will be recruited over 1 year for the 5-day protocol.

      Following a 72-hour washout period, factor levels and bone biomarkers will be followed before
      and after 50 units/kg replacement on Day 1 and 20 units/kg replacement on Day 3. Each subject
      can serve as their Figure 4. Fracture rates in PwH compared to historic controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FVIII replacement impact on the levels of biomarkers in bone metabolism</measure>
    <time_frame>5 days</time_frame>
    <description>Each subject can serve as their own control using baseline washout biomarker levels to compare with subsequent values after factor replacement. Fracture rates in PwH compared to historic controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and correlate the levels of biomarkers of bone metabolism with DEXA scan results, subject history, physical examination, quality of life and pain questionnaires.</measure>
    <time_frame>5 days</time_frame>
    <description>The subjects will also undergo a DEXA scan and answer several survey questions about their history and factor use.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemophilia</condition>
  <condition>Bone Disease</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everyone receives Advate (antihemophilic factor) on Day 1 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advate</intervention_name>
    <description>Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>Antihemophilic Factor (Recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males with a diagnosis of hemophilia A with a historic baseline FVIII level â‰¤ 2%.

          2. Age &gt; 16 years old

          3. Currently using ADVATE as FVIII replacement therapy

        Exclusion Criteria:

          1. Subject or guardian is unwilling or unable to give written informed consent and/or
             assent

          2. Joint or muscle bleeding within 2 weeks of Study Day 1

          3. Presence of a current factor inhibitor (&gt;0.6 BU/mL via Nijmegan-modified Bethesda
             assay)

          4. Known collagen vascular bone disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Taylor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alysia Cox</last_name>
    <phone>503-494-5109</phone>
    <email>coxal@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Lattimore, RN</last_name>
    <phone>503-418-4495</phone>
    <email>lattimor@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost. 2006 Mar;4(3):510-6.</citation>
    <PMID>16460432</PMID>
  </reference>
  <reference>
    <citation>Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri A, Ferretti M, Tradati FC, Santagostino E, von Mackensen S; Italian Association of Haemophilia Centres (AICE). Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost. 2009 May;7(5):780-6. doi: 10.1111/j.1538-7836.2009.03318.x. Epub 2009 Feb 12.</citation>
    <PMID>19220727</PMID>
  </reference>
  <reference>
    <citation>Gerstner G, Damiano ML, Tom A, Worman C, Schultz W, Recht M, Stopeck AT. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 2009 Mar;15(2):559-65. doi: 10.1111/j.1365-2516.2008.01963.x. Epub 2009 Feb 1.</citation>
    <PMID>19187193</PMID>
  </reference>
  <reference>
    <citation>Wallny TA, Scholz DT, Oldenburg J, Nicolay C, Ezziddin S, Pennekamp PH, Stoffel-Wagner B, Kraft CN. Osteoporosis in haemophilia - an underestimated comorbidity? Haemophilia. 2007 Jan;13(1):79-84.</citation>
    <PMID>17212729</PMID>
  </reference>
  <reference>
    <citation>Barnes C, Wong P, Egan B, Speller T, Cameron F, Jones G, Ekert H, Monagle P. Reduced bone density among children with severe hemophilia. Pediatrics. 2004 Aug;114(2):e177-81.</citation>
    <PMID>15286254</PMID>
  </reference>
  <reference>
    <citation>Gallacher SJ, Deighan C, Wallace AM, Cowan RA, Fraser WD, Fenner JA, Lowe GD, Boyle IT. Association of severe haemophilia A with osteoporosis: a densitometric and biochemical study. Q J Med. 1994 Mar;87(3):181-6.</citation>
    <PMID>8208906</PMID>
  </reference>
  <reference>
    <citation>Tlacuilo-Parra A, Morales-Zambrano R, Tostado-Rabago N, Esparza-Flores MA, Lopez-Guido B, Orozco-Alcala J. Inactivity is a risk factor for low bone mineral density among haemophilic children. Br J Haematol. 2008 Mar;140(5):562-7. doi: 10.1111/j.1365-2141.2007.06972.x.</citation>
    <PMID>18275434</PMID>
  </reference>
  <reference>
    <citation>Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006 Jan 1;42(1):108-14. Epub 2005 Nov 30. Review.</citation>
    <PMID>16323100</PMID>
  </reference>
  <reference>
    <citation>Anagnostis P, Vakalopoulou S, Vyzantiadis TA, Charizopoulou M, Karras S, Goulis DG, Karagiannis A, Gerou S, Garipidou V. The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B. Haemophilia. 2014 Mar;20(2):268-75. doi: 10.1111/hae.12271. Epub 2013 Oct 7.</citation>
    <PMID>24118364</PMID>
  </reference>
  <reference>
    <citation>Liel MS, Greenberg DL, Recht M, Vanek C, Klein RF, Taylor JA. Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency. Br J Haematol. 2012 Jul;158(1):140-3. doi: 10.1111/j.1365-2141.2012.09101.x. Epub 2012 Apr 2.</citation>
    <PMID>22469061</PMID>
  </reference>
  <reference>
    <citation>Kempton CL, Antun A, Antoniucci DM, Carpenter W, Ribeiro M, Stein S, Slovensky L, Elon L. Bone density in haemophilia: a single institutional cross-sectional study. Haemophilia. 2014 Jan;20(1):121-8. doi: 10.1111/hae.12240. Epub 2013 Aug 1.</citation>
    <PMID>23902277</PMID>
  </reference>
  <reference>
    <citation>Lee SK, Lorenzo J. Cytokines regulating osteoclast formation and function. Curr Opin Rheumatol. 2006 Jul;18(4):411-8. Review.</citation>
    <PMID>16763463</PMID>
  </reference>
  <reference>
    <citation>Brinker MR, O'Connor DP. The incidence of fractures and dislocations referred for orthopaedic services in a capitated population. J Bone Joint Surg Am. 2004 Feb;86-A(2):290-7.</citation>
    <PMID>14960673</PMID>
  </reference>
  <reference>
    <citation>Roche AF, Roberts J, Hamill PV. Skeletal maturity of youths 12--17 years racial, geographic area, and socioeconomic differentials. United States, 1966-1970. Vital Health Stat 11. 1978 Oct;(167):1-98.</citation>
    <PMID>214960</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jason Taylor, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemophilia</keyword>
  <keyword>bone disease</keyword>
  <keyword>clinical study</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

